On September 25th, the Indian Council for Medical Research (ICMR) announced that it has validated and approved Vstrip® COVID-19 Antigen Rapid Test as satisfactory and meets the minimum acceptance criteria of sensitivity and specificity of rapid antigen test kits.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the third quarter ended July 31, 2020.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the U.S. Food and Drug Administration (FDA) has cleared a new Investigational New Drug (IND) application for the initiation of an Investigator Sponsored Phase 1 clinical study of ADXS-504, the Company’s off-the-shelf neoantigen ADXS-HOT candidate for prostate cancer.

ALK gene fusion occurs in approximately 3%-5% of NSCLC patients. Currently, there are 5 FDA approved tyrosine kinase inhibitors (TKI): crizotinib (first generation), ceritinib, alectinib, brigatinib (second generation), lorlatinib (third generation).

Currently, olaparib has been approved by the US. FDA for treating HER2-negative breast cancer patients who had a germline BRCA mutation. In phase I/II MEDIOLA study, the activity of olaparib in combined with durvalumab in various solid tumors were examined.

Gene fusion is one of the tumourigenic mechanisms as a drug target. For example, ALK, ROS1, RET, and NTRK1/2/3 gene fusions are identified as the druggable mutation across solid tumors. NRG1 gene fusion is an other druggable fusion, which activates ErbB signal pathways and promotes tumor growth. Drugs for blocking ErbB signal pathways are considered as treatment options for cancers with NRG1 gene fusion.

EirGenix provides premium quality CDMO services for biologics, develop biosimilar, and gets official approval for rapid diagnostic kit.

JHL Biotech, Inc. has announced a signing of a Master Service Agreement (“MSA”) with Adimmune Corporation, a Taiwanese vaccine company, to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.

N/A

Autologous or allogeneic natural killer (NK) cells possess efficient cytotoxicity against tumor cells without severe side effects such as CRS or graft-versus-host disease (GvHD).